The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update

Handb Exp Pharmacol. 2022:268:117-133. doi: 10.1007/164_2021_506.

Abstract

Wheals and angioedema are the signature signs of urticaria, and itch is the key symptom. Urticaria, in most patients, is acute and resolves within days (acute urticaria, AU). Chronic urticaria (CU) can be of long duration and results not only in severely impaired quality of life but also has a socioeconomic impact due to work productivity impairment. In some patients with CU, the wheals and angioedema are induced exclusively by defined and definite triggers (chronic inducible urticaria, CIndU). In most patients with CU, wheals and angioedema develop unprompted, spontaneously (chronic spontaneous urticaria, CSU). The management of CU aims for the complete control and absence of its signs and symptoms. This is achieved, in most patients, by prophylactic treatment until spontaneous remission occurs. Modern, second-generation H1-antihistamines are the first-line therapy, with the option of updosing to fourfold, and omalizumab is used when this fails.

Keywords: Angioedema; Chronic; Hives; Inducible; Itch; Mast Cell; Pruritus; Spontaneous; Urticaria; Wheals.

MeSH terms

  • Anti-Allergic Agents* / therapeutic use
  • Chronic Disease
  • Chronic Urticaria*
  • Humans
  • Omalizumab / therapeutic use
  • Quality of Life
  • Urticaria* / diagnosis
  • Urticaria* / drug therapy
  • Urticaria* / etiology

Substances

  • Anti-Allergic Agents
  • Omalizumab